If you or someone you know struggles with sleep, a recent move by pharmaceutical giant Eli Lilly could significantly impact future treatment options. They're making a big bet on a new drug development strategy that could change how we approach sleep disorders.
Eli Lilly's stock (LLY) has been trending due to its recent acquisition of Versanis Bio, a clinical-stage company.
This move highlights Lilly's aggressive strategy to expand its drug pipeline, especially in metabolic diseases and potentially related conditions like sleep disorders, which often have overlapping patient populations.